Mosaic ImmunoEngineering Inc. (CPMV)
USD 0.65
(-22.25%)
USD 0.65
(-22.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 261.27 Thousand USD | -3.05% |
| 2021 | 269.49 Thousand USD | -41.13% |
| 2020 | 457.8 Thousand USD | -76.22% |
| 2019 | 1.92 Million USD | 0.0% |
| 2017 | 2.57 Million USD | -31.41% |
| 2016 | 3.76 Million USD | -1.63% |
| 2015 | 3.82 Million USD | -26.21% |
| 2014 | 5.18 Million USD | -23.82% |
| 2013 | 6.8 Million USD | -19.17% |
| 2012 | 8.41 Million USD | 3.4% |
| 2011 | 8.13 Million USD | -35.4% |
| 2010 | 12.59 Million USD | -54.05% |
| 2009 | 27.41 Million USD | -18.71% |
| 2008 | 33.72 Million USD | 32.62% |
| 2007 | 25.43 Million USD | -26.1% |
| 2006 | 34.41 Million USD | 185.09% |
| 2005 | 12.07 Million USD | 224.16% |
| 2004 | 3.72 Million USD | 302.06% |
| 2003 | 926.22 Thousand USD | 99.09% |
| 2002 | 465.23 Thousand USD | -50.22% |
| 2001 | 934.52 Thousand USD | -39.46% |
| 2000 | 1.54 Million USD | -43.52% |
| 1999 | 2.73 Million USD | 138.7% |
| 1998 | 1.14 Million USD | -47.71% |
| 1997 | 2.18 Million USD | 13.08% |
| 1996 | 1.93 Million USD | -6.92% |
| 1995 | 2.08 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | 285.52 Thousand USD | -22.7% |
| 2023 Q1 | 148.46 Thousand USD | -43.18% |
| 2023 Q2 | 369.36 Thousand USD | 148.78% |
| 2022 Q3 | 432.92 Thousand USD | 94.01% |
| 2022 Q4 | 261.27 Thousand USD | -39.65% |
| 2022 FY | 261.27 Thousand USD | -3.05% |
| 2022 Q1 | 403.59 Thousand USD | 49.76% |
| 2022 Q2 | 223.15 Thousand USD | -44.71% |
| 2021 Q3 | 445.65 Thousand USD | -26.01% |
| 2021 Q4 | 269.49 Thousand USD | -39.53% |
| 2021 FY | 269.49 Thousand USD | -41.13% |
| 2021 Q1 | 267.53 Thousand USD | -44.55% |
| 2021 Q2 | 602.32 Thousand USD | 125.14% |
| 2020 Q2 | 818.61 Thousand USD | -21.63% |
| 2020 Q4 | 482.48 Thousand USD | -21.74% |
| 2020 FY | 457.8 Thousand USD | -76.22% |
| 2020 Q1 | 1.04 Million USD | -18.5% |
| 2020 Q3 | 616.53 Thousand USD | -24.69% |
| 2019 FY | 1.92 Million USD | 0.0% |
| 2019 Q2 | 1.92 Million USD | -11.71% |
| 2019 Q3 | 1.61 Million USD | -15.93% |
| 2019 Q4 | 1.28 Million USD | -20.79% |
| 2019 Q1 | 2.18 Million USD | 0.38% |
| 2018 Q2 | 2.57 Million USD | -11.19% |
| 2018 Q4 | 2.17 Million USD | -7.99% |
| 2018 Q3 | 2.36 Million USD | -8.5% |
| 2018 Q1 | 2.9 Million USD | -6.64% |
| 2017 Q1 | 4.09 Million USD | -6.89% |
| 2017 Q4 | 3.11 Million USD | -11.06% |
| 2017 Q2 | 3.76 Million USD | -8.06% |
| 2017 Q3 | 3.49 Million USD | -6.98% |
| 2017 FY | 2.57 Million USD | -31.41% |
| 2016 FY | 3.76 Million USD | -1.63% |
| 2016 Q1 | 4.39 Million USD | -10.81% |
| 2016 Q4 | 4.39 Million USD | 27.08% |
| 2016 Q3 | 3.45 Million USD | -9.57% |
| 2016 Q2 | 3.82 Million USD | -12.96% |
| 2015 FY | 3.82 Million USD | -26.21% |
| 2015 Q1 | 5.57 Million USD | -3.4% |
| 2015 Q4 | 4.92 Million USD | -2.11% |
| 2015 Q2 | 5.18 Million USD | -7.1% |
| 2015 Q3 | 5.03 Million USD | -2.9% |
| 2014 FY | 5.18 Million USD | -23.82% |
| 2014 Q3 | 6.14 Million USD | -9.62% |
| 2014 Q4 | 5.77 Million USD | -6.07% |
| 2014 Q1 | 7.39 Million USD | -5.9% |
| 2014 Q2 | 6.8 Million USD | -7.99% |
| 2013 Q1 | 7.36 Million USD | -0.73% |
| 2013 FY | 6.8 Million USD | -19.17% |
| 2013 Q2 | 8.41 Million USD | 14.23% |
| 2013 Q4 | 7.85 Million USD | 0.57% |
| 2013 Q3 | 7.81 Million USD | -7.17% |
| 2012 Q1 | 8.94 Million USD | -11.63% |
| 2012 Q3 | 6.97 Million USD | -14.25% |
| 2012 FY | 8.41 Million USD | 3.4% |
| 2012 Q4 | 7.42 Million USD | 6.34% |
| 2012 Q2 | 8.13 Million USD | -9.01% |
| 2011 Q4 | 10.12 Million USD | -10.07% |
| 2011 FY | 8.13 Million USD | -35.4% |
| 2011 Q3 | 11.25 Million USD | -10.67% |
| 2011 Q2 | 12.59 Million USD | -14.8% |
| 2011 Q1 | 14.78 Million USD | -31.11% |
| 2010 FY | 12.59 Million USD | -54.05% |
| 2010 Q2 | 27.41 Million USD | -2.36% |
| 2010 Q3 | 25.42 Million USD | -7.26% |
| 2010 Q1 | 28.07 Million USD | -4.28% |
| 2010 Q4 | 21.46 Million USD | -15.59% |
| 2009 Q2 | 33.72 Million USD | -3.96% |
| 2009 Q3 | 32.56 Million USD | -3.45% |
| 2009 Q4 | 29.33 Million USD | -9.92% |
| 2009 Q1 | 35.11 Million USD | -6.44% |
| 2009 FY | 27.41 Million USD | -18.71% |
| 2008 Q2 | 25.43 Million USD | -9.03% |
| 2008 FY | 33.72 Million USD | 32.62% |
| 2008 Q1 | 27.95 Million USD | 23.26% |
| 2008 Q4 | 37.53 Million USD | 21.37% |
| 2008 Q3 | 30.92 Million USD | 21.6% |
| 2007 Q3 | 24.13 Million USD | -29.88% |
| 2007 FY | 25.43 Million USD | -26.1% |
| 2007 Q4 | 22.68 Million USD | -6.01% |
| 2007 Q1 | 28.13 Million USD | 18.47% |
| 2007 Q2 | 34.41 Million USD | 22.31% |
| 2006 Q1 | 59.05 Million USD | 483.64% |
| 2006 Q4 | 23.75 Million USD | 14.91% |
| 2006 Q3 | 20.66 Million USD | 71.22% |
| 2006 Q2 | 12.07 Million USD | -79.56% |
| 2006 FY | 34.41 Million USD | 185.09% |
| 2005 FY | 12.07 Million USD | 224.16% |
| 2005 Q4 | 10.11 Million USD | -15.34% |
| 2005 Q3 | 11.95 Million USD | 220.93% |
| 2005 Q2 | 3.72 Million USD | -8.47% |
| 2005 Q1 | 4.06 Million USD | 589.07% |
| 2004 FY | 3.72 Million USD | 302.06% |
| 2004 Q4 | 590.46 Thousand USD | 10.07% |
| 2004 Q1 | 598.92 Thousand USD | 28.44% |
| 2004 Q2 | 926.22 Thousand USD | 54.65% |
| 2004 Q3 | 536.42 Thousand USD | -42.08% |
| 2003 Q4 | 466.3 Thousand USD | 9.74% |
| 2003 Q3 | 424.93 Thousand USD | -8.66% |
| 2003 Q2 | 465.23 Thousand USD | -21.44% |
| 2003 Q1 | 592.19 Thousand USD | -10.68% |
| 2003 FY | 926.22 Thousand USD | 99.09% |
| 2002 FY | 465.23 Thousand USD | -50.22% |
| 2002 Q3 | 743.1 Thousand USD | -20.48% |
| 2002 Q1 | 828.6 Thousand USD | 7.3% |
| 2002 Q2 | 934.52 Thousand USD | 12.78% |
| 2002 Q4 | 662.97 Thousand USD | -10.78% |
| 2001 Q4 | 772.22 Thousand USD | -32.17% |
| 2001 FY | 934.52 Thousand USD | -39.46% |
| 2001 Q1 | 1.16 Million USD | -44.52% |
| 2001 Q2 | 1.54 Million USD | 32.4% |
| 2001 Q3 | 1.13 Million USD | -26.25% |
| 2000 FY | 1.54 Million USD | -43.52% |
| 2000 Q3 | 1.66 Million USD | -38.97% |
| 2000 Q2 | 2.73 Million USD | -25.85% |
| 2000 Q4 | 2.1 Million USD | 25.99% |
| 2000 Q1 | 3.68 Million USD | 271.41% |
| 1999 Q3 | 1.06 Million USD | 0.0% |
| 1999 FY | 2.73 Million USD | 138.7% |
| 1999 Q4 | 992.46 Thousand USD | -6.58% |
| 1998 FY | 1.14 Million USD | -47.71% |
| 1997 FY | 2.18 Million USD | 13.08% |
| 1996 FY | 1.93 Million USD | -6.92% |
| 1995 FY | 2.08 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -11210.693% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 86.657% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 97.524% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 52.677% |
| Rebus Holdings, Inc. | 5000.00 USD | -5125.54% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.799% |
| Qrons Inc. | 420.00 USD | -62108.81% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 66.096% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.065% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 45.63% |
| Skye Bioscience, Inc. | 11.94 Million USD | 97.812% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.327% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 96.381% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -242.192% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.756% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 81.755% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -261.054% |
| Mesoblast Limited | 667.9 Million USD | 99.961% |
| Marizyme, Inc. | 22.01 Million USD | 98.813% |
| Genus plc | 1.02 Billion USD | 99.975% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 80.765% |
| Pharming Group N.V. | 462.85 Million USD | 99.944% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 92.114% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 47.644% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 58.329% |
| ContraFect Corporation | 20.67 Million USD | 98.737% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 33.069% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 31.635% |
| IMV Inc. | 31.33 Million USD | 99.166% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 93.698% |
| MultiCell Technologies, Inc. | 126.22 USD | -206901.268% |
| ONE Bio Corp. | 70.08 Million USD | 99.627% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 72.195% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.797% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 39.479% |
| Q BioMed Inc. | 3.51 Million USD | 92.568% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.257% |
| Biomind Labs Inc. | 73.81 Thousand USD | -253.943% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.941% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 81.967% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.13% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 90.486% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 61.995% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 89.963% |
| GB Sciences, Inc. | 103.44 Thousand USD | -152.583% |
| Alpha Cognition Inc. | 2.45 Million USD | 89.345% |
| HST Global, Inc. | 1526.00 USD | -17021.691% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 73.554% |
| Halberd Corporation | 10.13 Thousand USD | -2478.985% |
| Enzolytics Inc. | 361.7 Million USD | 99.928% |
| Agentix Corp. | 261.39 Thousand USD | 0.044% |
| Resverlogix Corp. | 8.11 Million USD | 96.78% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 86.087% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.994% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.452% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 59.154% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1046.908% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 97.08% |
| AVAX Technologies, Inc. | 7.37 Million USD | 96.458% |
| Zenith Capital Corp. | 7410.00 USD | -3426.005% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.992% |
| Ember Therapeutics, Inc. | 184.00 USD | -141898.37% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 18.809% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 0.033% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 71.844% |
| Kadimastem Ltd | 2.3 Million USD | 88.66% |
| Helix BioMedix, Inc. | 3.02 Million USD | 91.363% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.504% |
| BioStem Technologies, Inc. | 14.56 Million USD | 98.206% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -357.626% |
| LadRx Corporation | 2.3 Million USD | 88.679% |
| Cell Source, Inc. | 195.17 Thousand USD | -33.871% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 26.113% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 26.113% |
| NovAccess Global Inc. | 62.24 Thousand USD | -319.736% |
| Affymax, Inc. | 7.44 Million USD | 96.49% |
| Itoco Inc. | 1.4 Million USD | 81.338% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -173.139% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -146.488% |
| Mobile Lads Corp. | 52.00 USD | -502355.769% |
| CytoDyn Inc. | 11.13 Million USD | 97.654% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -82.747% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1361.281% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 32.219% |
| SYBLEU INC | 330.46 Thousand USD | 20.937% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 36.184% |
| International Stem Cell Corporation | 5.39 Million USD | 95.153% |
| Bioxytran, Inc. | 137.63 Thousand USD | -89.829% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 98.258% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 98.424% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -230.73% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 69.783% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 96.524% |
| Neutra Corp. | 2851.00 USD | -9064.398% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.194% |
| PureTech Health plc | 693.97 Million USD | 99.962% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 96.763% |
| IXICO plc | 15.84 Million USD | 98.351% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 96.845% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.747% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.922% |